IRON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Disc Medicine Inc (IRON) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock faces significant uncertainties due to FDA-related delays, ongoing lawsuits, and lack of clear positive catalysts. While analysts maintain generally positive ratings, the risks outweigh the potential rewards in the short to medium term. Holding off on investment until more clarity emerges is advisable.
The MACD is positively expanding, indicating bullish momentum. RSI is in the neutral zone at 71.578, showing no overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key resistance is at 65.999, and support is at 58.809. The stock closed at 64, slightly below the resistance level.
Analysts remain optimistic about the long-term potential of bitopertin, with several maintaining Buy or Overweight ratings despite recent setbacks. The ongoing Phase 3 APOLLO trial could provide clarity by Q4 2026.
The FDA's Complete Response Letter and subsequent delays have negatively impacted investor sentiment. Multiple law firms are investigating potential securities fraud and governance issues, creating additional uncertainty. The company's financials show no revenue and significant losses, with no clear path to profitability in the near term.
In Q4 2025, revenue remained at $0, showing no growth. Net income improved YoY but remains deeply negative at -$60.53 million. EPS improved to -1.61, reflecting reduced losses but still negative. Gross margin is nonexistent, indicating no operational profitability.
Analysts have mixed views, with price targets ranging from $75 to $125. While many maintain Buy or Overweight ratings, recent price target reductions reflect increased clinical risk and uncertainty surrounding the FDA's decision-making process.
